{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:55Z","timestamp":1791972775829,"version":"4.3.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institutes of Health, United States","award":["T32 CA 009599"],"award-info":[{"award-number":["T32 CA 009599"]}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11912-024-01610-w","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:46:16Z","timestamp":1730108776000},"page":"1530-1542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors"],"prefix":"10.1007","volume":"26","author":[{"given":"Brittany C.","family":"Fields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed I.","family":"Ayabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. David","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"1","key":"1610_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"key":"1610_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.14694\/EdBook_AM.2015.35.92","volume":"35","author":"DS Klimstra","year":"2015","unstructured":"Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015;35:92\u2013103. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.92.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"32","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023;41(32):5049\u201367. https:\/\/doi.org\/10.1200\/JCO.23.01529.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5662\/wjm.v12.i5.381","volume":"12","author":"JG Gonzales-Yovera","year":"2022","unstructured":"Gonzales-Yovera JG, et al. Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. World J Methodol. 2022;12(5):381\u201391. https:\/\/doi.org\/10.5662\/wjm.v12.i5.381.","journal-title":"World J Methodol"},{"issue":"3","key":"1610_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1572-0241.2007.01777.x","volume":"103","author":"CG Toumpanakis","year":"2008","unstructured":"Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103(3):729\u201332. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01777.x.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1610_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1610_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/medsci7030046","volume":"7","author":"A Barsouk","year":"2019","unstructured":"Barsouk A, Rawla P, Barsouk A, Thandra KC. Epidemiology of Cancers of the Small Intestine: Trends, Risk Factors, and Prevention. Med Sci (Basel). 2019;7(3):46. https:\/\/doi.org\/10.3390\/medsci7030046.","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/RCT.0000000000001541","volume":"48","author":"SS Vulasala","year":"2023","unstructured":"Vulasala SS, et al. Small Bowel Neuroendocrine Neoplasms-A Review. J Comput Assist Tomogr. 2023;48(4):563. https:\/\/doi.org\/10.1097\/RCT.0000000000001541.","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00261-020-02773-3","volume":"46","author":"S Malla","year":"2021","unstructured":"Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review. Abdom Radiol (NY). 2021;46(3):919\u201335. https:\/\/doi.org\/10.1007\/s00261-020-02773-3.","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2015.04.008","volume":"149","author":"Y Sei","year":"2015","unstructured":"Sei Y, et al. A Hereditary Form of Small Intestinal Carcinoid Associated With a Germline Mutation in Inositol Polyphosphate Multikinase. Gastroenterology. 2015;149(1):67\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.008.","journal-title":"Gastroenterology"},{"issue":"8","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/ERC-17-0196","volume":"24","author":"JP Dumanski","year":"2017","unstructured":"Dumanski JP, et al. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocr Relat Cancer. 2017;24(8):427\u201343. https:\/\/doi.org\/10.1530\/ERC-17-0196.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1148\/radiol.12112512","volume":"266","author":"DV Sahani","year":"2013","unstructured":"Sahani DV, Bonaffini PA, Fernandez-Del Castillo C, Blake MA. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology. 2013;266(1):38\u201361. https:\/\/doi.org\/10.1148\/radiol.12112512.","journal-title":"Radiology."},{"issue":"6","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1148\/rg.276075001","volume":"27","author":"S Chang","year":"2007","unstructured":"Chang S, et al. Neuroendocrine neoplasms of the gastrointestinal tract: classification, pathologic basis, and imaging features. Radiographics. 2007;27(6):1667\u201379. https:\/\/doi.org\/10.1148\/rg.276075001.","journal-title":"Radiographics."},{"issue":"12","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/ng.2821","volume":"45","author":"JM Francis","year":"2013","unstructured":"Francis JM, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483\u20136. https:\/\/doi.org\/10.1038\/ng.2821.","journal-title":"Nat Genet"},{"issue":"4","key":"1610_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4143\/crt.2013.102","volume":"46","author":"HS Kim","year":"2014","unstructured":"Kim HS, Lee HS, Nam KH, Choi J, Kim WH. p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors. Cancer Res Treat. 2014;46(4):383\u201392. https:\/\/doi.org\/10.4143\/crt.2013.102.","journal-title":"Cancer Res Treat"},{"issue":"4","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1530\/ERC-18-0332","volume":"26","author":"J Yao","year":"2019","unstructured":"Yao J, et al. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019;26(4):391\u2013403. https:\/\/doi.org\/10.1530\/ERC-18-0332.","journal-title":"Endocr Relat Cancer"},{"key":"1610_CR17","doi-asserted-by":"publisher","first-page":"622693","DOI":"10.3389\/fendo.2021.622693","volume":"12","author":"JY Lim","year":"2021","unstructured":"Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne). 2021;12:622693. https:\/\/doi.org\/10.3389\/fendo.2021.622693.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1610_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ando.2019.04.010","volume":"80","author":"A Scarpa","year":"2019","unstructured":"Scarpa A. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol (Paris). 2019;80(3):153\u20138. https:\/\/doi.org\/10.1016\/j.ando.2019.04.010.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"8","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/cancers16081553","volume":"16","author":"A Vishwanath","year":"2024","unstructured":"Vishwanath A, Krishna S, Manudhane AP, Hart PA, Krishna SG. Early-Onset Gastrointestinal Malignancies: An Investigation into a Rising Concern. Cancers (Basel). 2024;16(8):1553. https:\/\/doi.org\/10.3390\/cancers16081553.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1\u201318. https:\/\/doi.org\/10.1016\/j.ecl.2010.12.005.","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"10","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","volume":"13","author":"H Yousefi","year":"2017","unstructured":"Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017;13(10):1001\u201315. https:\/\/doi.org\/10.1080\/1744666X.2017.1366315.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3\u20134","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","volume":"130","author":"C Thallinger","year":"2018","unstructured":"Thallinger C, et al. Review of cancer treatment with immune checkpoint inhibitors\u202f: Current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr. 2018;130(3\u20134):85\u201391. https:\/\/doi.org\/10.1007\/s00508-017-1285-9.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","volume":"51","author":"M Simsek","year":"2019","unstructured":"Simsek M, Tekin SB, Bilici M. Immunological Agents Used in Cancer Treatment. Eurasian J Med. 2019;51(1):90\u20134. https:\/\/doi.org\/10.5152\/eurasianjmed.2018.18194.","journal-title":"Eurasian J Med"},{"issue":"4","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","volume":"17","author":"N Chhabra","year":"2021","unstructured":"Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol. 2021;17(4):411\u201324. https:\/\/doi.org\/10.1007\/s13181-021-00833-8.","journal-title":"J Med Toxicol"},{"issue":"9","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/cancers11091395","volume":"11","author":"V Larouche","year":"2019","unstructured":"Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel). 2019;11(9):1395. https:\/\/doi.org\/10.3390\/cancers11091395.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JOP.18.00135","volume":"14","author":"AT Scott","year":"2018","unstructured":"Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14(8):471\u201382. https:\/\/doi.org\/10.1200\/JOP.18.00135.","journal-title":"J Oncol Pract"},{"issue":"3","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djx174","volume":"110","author":"M Cives","year":"2018","unstructured":"Cives M, Anaya DA, Soares H, Coppola D, Strosberg J. Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst. 2018;110(3):282\u20139. https:\/\/doi.org\/10.1093\/jnci\/djx174.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.dld.2011.04.021","volume":"43","author":"C Le Roux","year":"2011","unstructured":"Le Roux C, et al. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Dig Liver Dis. 2011;43(10):828\u201333. https:\/\/doi.org\/10.1016\/j.dld.2011.04.021.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/02841869309083915","volume":"32","author":"L Anthony","year":"1993","unstructured":"Anthony L, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217\u201323. https:\/\/doi.org\/10.3109\/02841869309083915.","journal-title":"Acta Oncol"},{"issue":"7","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s11864-022-00983-z","volume":"23","author":"T Alonso-Gordoa","year":"2022","unstructured":"Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol. 2022;23(7):1001\u201313. https:\/\/doi.org\/10.1007\/s11864-022-00983-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"1610_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12032-018-1189-1","volume":"35","author":"SC Lau","year":"2018","unstructured":"Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol. 2018;35(9):123. https:\/\/doi.org\/10.1007\/s12032-018-1189-1.","journal-title":"Med Oncol"},{"issue":"3","key":"1610_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"issue":"28","key":"1610_CR33","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, et al. Placebo-controlled, double-blind prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1009290.","journal-title":"N Engl J Med"},{"issue":"10022","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X.","journal-title":"Lancet"},{"key":"1610_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","volume":"44","author":"A Lamarca","year":"2016","unstructured":"Lamarca A, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cancer Treat Rev. 2016;44:26\u201341. https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.005.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1610_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","volume":"21","author":"RA Ramirez","year":"2016","unstructured":"Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The Role of Capecitabine\/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21(6):671\u20135. https:\/\/doi.org\/10.1634\/theoncologist.2015-0470.","journal-title":"Oncologist"},{"issue":"2","key":"1610_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"10446","key":"1610_CR39","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"issue":"2","key":"1610_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00259-013-2578-5","volume":"41","author":"E Seregni","year":"2014","unstructured":"Seregni E, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41(2):223\u201330. https:\/\/doi.org\/10.1007\/s00259-013-2578-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1610_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/RLU.0000000000005149","volume":"49","author":"H Yang","year":"2024","unstructured":"Yang H, et al. Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression. Clin Nucl Med. 2024;49(6):505\u201312. https:\/\/doi.org\/10.1097\/RLU.0000000000005149.","journal-title":"Clin Nucl Med"},{"issue":"13","key":"1610_CR42","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/cncr.32883","volume":"126","author":"JM Mehnert","year":"2020","unstructured":"Mehnert JM, et al. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020;126(13):3021\u201330. https:\/\/doi.org\/10.1002\/cncr.32883.","journal-title":"Cancer"},{"issue":"2","key":"1610_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1610_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.21037\/jgo.2016.12.09","volume":"8","author":"IH Liu","year":"2017","unstructured":"Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2017;8(3):457\u201365. https:\/\/doi.org\/10.21037\/jgo.2016.12.09.","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"1610_CR45","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","volume":"26","author":"M Lu","year":"2020","unstructured":"Lu M, et al. Efficacy Safety and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020;26(10):2337\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4000.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1610_CR46","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","volume":"26","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020;26(9):2124\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3014.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1610_CR47","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","volume":"26","author":"SP Patel","year":"2020","unstructured":"Patel SP, et al. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020;26(10):2290\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3356.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1610_CR48","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","volume":"26","author":"O Klein","year":"2020","unstructured":"Klein O, et al. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clin Cancer Res. 2020;26(17):4454\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0621.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1610_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512\u20139. https:\/\/doi.org\/10.1007\/s00535-016-1263-4.","journal-title":"J Gastroenterol"},{"issue":"10126","key":"1610_CR50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"26","key":"1610_CR51","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960\u201370. https:\/\/doi.org\/10.1200\/JCO.20.00808.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1610_CR52","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/bjc.2012.154","volume":"106","author":"DS Boss","year":"2012","unstructured":"Boss DS, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598\u2013604. https:\/\/doi.org\/10.1038\/bjc.2012.154.","journal-title":"Br J Cancer"},{"issue":"15","key":"1610_CR53","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Lenvatinib, everolimus and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2 open-label multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(15)00290-9.","journal-title":"Lancet Oncol"},{"key":"1610_CR54","doi-asserted-by":"publisher","unstructured":"C. H. Lee et al., 2024 \"Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111\/KEYNOTE-146\". Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.003","DOI":"10.1016\/j.eururo.2024.05.003"},{"issue":"3","key":"1610_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2021.06.032","volume":"162","author":"FJ Backes","year":"2021","unstructured":"Backes FJ, et al. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecol Oncol. 2021;162(3):619\u201325. https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.032.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"1610_CR56","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","volume":"39","author":"J Capdevila","year":"2021","unstructured":"Capdevila J, et al. Lenvatinib in Patients With Advanced Grade 1\/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). J Clin Oncol. 2021;39(20):2304\u201312. https:\/\/doi.org\/10.1200\/JCO.20.03368.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1610_CR57","doi-asserted-by":"publisher","first-page":"102386","DOI":"10.1016\/j.esmoop.2024.102386","volume":"9","author":"T Al-Toubah","year":"2024","unstructured":"Al-Toubah T, Schell MJ, Morse B, Haider M, Valone T, Strosberg J. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. ESMO Open. 2024;9(4):102386. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102386.","journal-title":"ESMO Open"},{"issue":"3","key":"1610_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-20-0382","volume":"28","author":"JC Yao","year":"2021","unstructured":"Yao JC, et al. Spartalizumab in metastatic, well\/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021;28(3):161. https:\/\/doi.org\/10.1530\/ERC-20-0382.","journal-title":"Endocr Relat Cancer"},{"key":"1610_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","volume":"169","author":"DL Chan","year":"2022","unstructured":"Chan DL, et al. Avelumab in unresectable\/metastatic, progressive, grade 2\u20133 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022;169:74\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.029.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1610_CR60","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","volume":"8","author":"DM Halperin","year":"2022","unstructured":"Halperin DM, et al. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022;8(6):904\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0212.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1610_CR61","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1093\/oncolo\/oyac097","volume":"27","author":"R Jia","year":"2022","unstructured":"Jia R, et al. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms. Oncologist. 2022;27(8):e625\u201332. https:\/\/doi.org\/10.1093\/oncolo\/oyac097.","journal-title":"Oncologist"},{"issue":"1","key":"1610_CR62","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","volume":"14","author":"J Capdevila","year":"2023","unstructured":"Capdevila J, et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023;14(1):2973. https:\/\/doi.org\/10.1038\/s41467-023-38611-5.","journal-title":"Nat Commun"},{"key":"1610_CR63","unstructured":"\"Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors,\" December 19, 2023 ed.\u00a0NCT05746208."},{"key":"1610_CR64","unstructured":"\"A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1),\" March 29, 2024 ed.\u00a0NCT05086692."},{"key":"1610_CR65","unstructured":"\"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours,\" August 2, 2022 ed.\u00a0NCT04525638."},{"key":"1610_CR66","doi-asserted-by":"publisher","unstructured":"Enrique Grande et al. Cabozantinib plus atezolizumab in locally advanced\/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN\/GETNE-T1914.\u00a0J Clin Oncol. 2024;42:1\u20131. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.1.","DOI":"10.1200\/JCO.2024.42.4_suppl.1"},{"key":"1610_CR67","unstructured":"\"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,\" March 15, 2024 ed"},{"key":"1610_CR68","doi-asserted-by":"publisher","unstructured":"Prenen H, Lesimple T, Robert M, et al. A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0734.","DOI":"10.1136\/jitc-2022-SITC2022.0734"},{"key":"1610_CR69","doi-asserted-by":"crossref","unstructured":"Sarantopoulos J, et al. A phase Ia\/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours. Ann Oncol. Volume 30, v172.","DOI":"10.1093\/annonc\/mdz244.022"},{"key":"1610_CR70","doi-asserted-by":"publisher","unstructured":"Hong D, et al. Phase I\/II study of LAG525 \u00b1 spartalizumab (PDR001) in patients (pts) withadvanced malignancies. J Clin Oncol. 2018;36:3012\u20133012. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.3012.","DOI":"10.1200\/JCO.2018.36.15_suppl.3012"},{"key":"1610_CR71","doi-asserted-by":"crossref","unstructured":"D. Hong et al., 2020 \"380\u2005Preliminary results of an ongoing phase I trial of FT500 a first-in-class, off-the-shelf induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors\" Journal for ImmunoTherapy of Cancer. 8 A231-A232","DOI":"10.1136\/jitc-2020-SITC2020.0380"},{"issue":"1","key":"1610_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"12","key":"1610_CR73","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"12","key":"1610_CR74","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/modpathol.3800490","volume":"18","author":"L Liu","year":"2005","unstructured":"Liu L, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1 isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005;18(12):1632\u201340. https:\/\/doi.org\/10.1038\/modpathol.3800490.","journal-title":"Mod Pathol"},{"issue":"4","key":"1610_CR75","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/path.1784","volume":"206","author":"S Pizzi","year":"2005","unstructured":"Pizzi S, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005;206(4):409\u201316. https:\/\/doi.org\/10.1002\/path.1784.","journal-title":"J Pathol"},{"key":"1610_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-061813-012908","volume":"66","author":"DM Halperin","year":"2015","unstructured":"Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015;66:1\u201316. https:\/\/doi.org\/10.1146\/annurev-med-061813-012908.","journal-title":"Annu Rev Med"},{"issue":"12","key":"1610_CR77","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","volume":"9","author":"FI Montalto","year":"2020","unstructured":"Montalto FI, De Amicis F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control Adhesion and Invasion in Tumor and Stroma. Cells. 2020;9(12):2648. https:\/\/doi.org\/10.3390\/cells9122648.","journal-title":"Cells"},{"key":"1610_CR78","doi-asserted-by":"publisher","first-page":"106767","DOI":"10.1016\/j.ejps.2024.106767","volume":"197","author":"W Fan","year":"2024","unstructured":"Fan W, et al. Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer. Eur J Pharm Sci. 2024;197:106767. https:\/\/doi.org\/10.1016\/j.ejps.2024.106767.","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"1610_CR79","doi-asserted-by":"publisher","first-page":"e075221","DOI":"10.1136\/bmjopen-2023-075221","volume":"13","author":"R Murphy","year":"2023","unstructured":"Murphy R, et al. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. BMJ Open. 2023;13(10):e075221. https:\/\/doi.org\/10.1136\/bmjopen-2023-075221.","journal-title":"BMJ Open"},{"key":"1610_CR80","doi-asserted-by":"publisher","first-page":"901435","DOI":"10.3389\/fonc.2022.901435","volume":"12","author":"JS Crabtree","year":"2022","unstructured":"Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol. 2022;12:901435. https:\/\/doi.org\/10.3389\/fonc.2022.901435.","journal-title":"Front Oncol"},{"issue":"7","key":"1610_CR81","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1634\/theoncologist.2016-0060","volume":"21","author":"N Jin","year":"2016","unstructured":"Jin N, et al. A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist. 2016;21(7):785\u20136. https:\/\/doi.org\/10.1634\/theoncologist.2016-0060.","journal-title":"Oncologist"},{"issue":"5","key":"1610_CR82","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/CAD.0000000000000596","volume":"29","author":"S Balasubramaniam","year":"2018","unstructured":"Balasubramaniam S, et al. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anticancer Drugs. 2018;29(5):457\u201365. https:\/\/doi.org\/10.1097\/CAD.0000000000000596.","journal-title":"Anticancer Drugs"},{"key":"1610_CR83","doi-asserted-by":"publisher","unstructured":"J. Greenberg et al., 2022 \"Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration,\" JCI Insight. 7 23. https:\/\/doi.org\/10.1172\/jci.insight.160130","DOI":"10.1172\/jci.insight.160130"},{"issue":"6","key":"1610_CR84","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cells10061408","volume":"10","author":"RL Schmitz","year":"2021","unstructured":"Schmitz RL, et al. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models. Cells. 2021;10(6):1408. https:\/\/doi.org\/10.3390\/cells10061408.","journal-title":"Cells"},{"issue":"13","key":"1610_CR85","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","volume":"12","author":"MH Shah","year":"2006","unstructured":"Shah MH, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997\u20134003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2689.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1610_CR86","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/oncolo\/oyae118","volume":"29","author":"JK Jamison","year":"2024","unstructured":"Jamison JK, et al. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Oncologist. 2024;29(9):817. https:\/\/doi.org\/10.1093\/oncolo\/oyae118.","journal-title":"Oncologist"},{"issue":"12","key":"1610_CR87","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","volume":"21","author":"HZ Lee","year":"2015","unstructured":"Lee HZ, et al. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2015;21(12):2666\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3119.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1610_CR88","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247\u201352. https:\/\/doi.org\/10.1634\/theoncologist.12-10-1247.","journal-title":"Oncologist"},{"key":"1610_CR89","doi-asserted-by":"publisher","first-page":"514261","DOI":"10.1155\/2011\/514261","volume":"2011","author":"CP Miller","year":"2011","unstructured":"Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011;2011:514261. https:\/\/doi.org\/10.1155\/2011\/514261.","journal-title":"J Biomed Biotechnol"},{"issue":"11","key":"1610_CR90","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"1","key":"1610_CR91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60\u20135. https:\/\/doi.org\/10.1200\/JCO.2003.10.066.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1610_CR92","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.3390\/cancers13194872","volume":"13","author":"S Das","year":"2021","unstructured":"Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel). 2021;13(19):4872. https:\/\/doi.org\/10.3390\/cancers13194872.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1610_CR93","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"1610_CR94","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1610_CR95","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-15-0119","volume":"22","author":"M Heetfeld","year":"2015","unstructured":"Heetfeld M, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657\u201364. https:\/\/doi.org\/10.1530\/ERC-15-0119.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1610_CR96","doi-asserted-by":"publisher","first-page":"e0158140","DOI":"10.1371\/journal.pone.0158140","volume":"11","author":"MH Wong","year":"2016","unstructured":"Wong MH, et al. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS ONE. 2016;11(6):e0158140. https:\/\/doi.org\/10.1371\/journal.pone.0158140.","journal-title":"PLoS ONE"},{"key":"1610_CR97","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.3390\/jcm12020717","volume":"12","author":"A Zappi","year":"2023","unstructured":"Zappi A, et al. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. J Clin Med. 2023;12:2717. https:\/\/doi.org\/10.3390\/jcm12020717.","journal-title":"J Clin Med"},{"key":"1610_CR98","doi-asserted-by":"publisher","unstructured":"N. J. Galbraith and C. M. Sokas, 2024 \"Small Bowel Neuroendocrine Tumors\" Dis Colon Rectum. https:\/\/doi.org\/10.1097\/DCR.0000000000003387","DOI":"10.1097\/DCR.0000000000003387"},{"issue":"4","key":"1610_CR99","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/curroncol31040154","volume":"31","author":"CR Criss","year":"2024","unstructured":"Criss CR, Makary MS. Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management. Curr Oncol. 2024;31(4):2076\u201391. https:\/\/doi.org\/10.3390\/curroncol31040154.","journal-title":"Curr Oncol"},{"issue":"2","key":"1610_CR100","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11523-012-0219-8","volume":"7","author":"M Zappa","year":"2012","unstructured":"Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol. 2012;7(2):107\u201316. https:\/\/doi.org\/10.1007\/s11523-012-0219-8.","journal-title":"Target Oncol"},{"issue":"1","key":"1610_CR101","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0033-1333651","volume":"30","author":"S Gupta","year":"2013","unstructured":"Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol. 2013;30(1):28\u201338. https:\/\/doi.org\/10.1055\/s-0033-1333651.","journal-title":"Semin Intervent Radiol"},{"issue":"6","key":"1610_CR102","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/0284186X.2023.2218554","volume":"62","author":"A DowlerNygaard","year":"2023","unstructured":"DowlerNygaard A, Aggerholm Pedersen N, Dam GA, Knap MM, Tabaksblat EM. Local disease control after stereotactic body radiotherapy in patients with neuroendocrine neoplasms: a cohort study. Acta Oncol. 2023;62(6):621\u20136. https:\/\/doi.org\/10.1080\/0284186X.2023.2218554.","journal-title":"Acta Oncol"},{"issue":"6","key":"1610_CR103","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","volume":"148","author":"HY Akyildiz","year":"2010","unstructured":"Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148(6):1288\u201393. https:\/\/doi.org\/10.1016\/j.surg.2010.09.014.","journal-title":"Surgery"},{"key":"1610_CR104","doi-asserted-by":"publisher","first-page":"1153066","DOI":"10.3389\/fonc.2023.1153066","volume":"13","author":"M Jiang","year":"2023","unstructured":"Jiang M, Fiering S, Shao Q. Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials. Front Oncol. 2023;13:1153066. https:\/\/doi.org\/10.3389\/fonc.2023.1153066.","journal-title":"Front Oncol"},{"issue":"2","key":"1610_CR105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.17998\/jlc.2022.03.28","volume":"22","author":"DH Kim","year":"2022","unstructured":"Kim DH. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. J Liver Cancer. 2022;22(2):93\u2013102. https:\/\/doi.org\/10.17998\/jlc.2022.03.28.","journal-title":"J Liver Cancer"},{"issue":"6","key":"1610_CR106","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.21037\/tlcr-20-1075","volume":"10","author":"K Rangamuwa","year":"2021","unstructured":"Rangamuwa K, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021;10(6):2842\u201357. https:\/\/doi.org\/10.21037\/tlcr-20-1075.","journal-title":"Transl Lung Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01610-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:00:49Z","timestamp":1732093249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01610-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":106,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01610-w","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"30 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To the best of their knowledge, the authors confirm that the human subject studies referenced in this article were performed in accordance with the guidelines specified by the Declaration of Helsinki and the appropriate institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Brittany C. Fields, Reed I. Ayabe, Y. David Seo, and Jessica E. Maxwell declare no conflicts of interest. Daniel M. Halperin has received clinical trial funding from Genentech\/Roche; RayzeBio, and Thermo Fisher Scientific; grants and personal fees from AAA\/Novartis, Camurus, and ITM; and personal fees from Exelixis, Harpoon Tx, Amryt Pharma, Ipsen, Lexicon, TerSera, Curium, AlphaMedix,, Crinetics, and Chimeric Therapeutics outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}